At a glance
- Originator Sankyo
- Class Antihyperlipidaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 05 Dec 2003 No development reported - Preclinical for Hyperlipidaemia in Japan (unspecified route)
- 21 Jul 1997 New profile
- 21 Jul 1997 Preclinical development for Hyperlipidaemia in Japan (Unknown route)